U.S. Healthcare Bioconvergence Market Size & Outlook
U.S. healthcare bioconvergence market, 2017-2030 (US$M)
Related Markets
U.S. healthcare bioconvergence market highlights
- The U.S. healthcare bioconvergence market generated a revenue of USD 30,006.2 million in 2022 and is expected to reach USD 51,125.3 million by 2030.
- The U.S. market is expected to grow at a CAGR of 6.9% from 2023 to 2030.
- In terms of segment, drug discovery was the largest revenue generating application in 2022.
- Nanorobotics for Drug Delivery is the most lucrative application segment registering the fastest growth during the forecast period.
Healthcare bioconvergence market data book summary
| Market revenue in 2022 | USD 30,006.2 million |
| Market revenue in 2030 | USD 51,125.3 million |
| Growth rate | 6.9% (CAGR from 2022 to 2030) |
| Largest segment | Drug discovery |
| Fastest growing segment | Nanorobotics for Drug Delivery |
| Historical data | 2017 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Drug Discovery, Nanorobotics for Drug Delivery, Regenerative Medicine, Diagnostic and Biological, Bioelectronics, Engineered Living Materials, Optogenetics, Precision Medicine |
| Key market players worldwide | BiomX Inc, Ginkgo Bioworks Holdings Inc, SetPoint Medical, GSK PLC, BICO |
Other key industry trends
- In terms of revenue, U.S. accounted for 24.7% of the global healthcare bioconvergence market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. healthcare bioconvergence market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 8,796.5 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Healthcare Bioconvergence Market Scope
Healthcare Bioconvergence Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. healthcare bioconvergence market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to healthcare bioconvergence market will help companies and investors design strategic landscapes.
Drug discovery was the largest segment with a revenue share of 20.96% in 2022. Horizon Databook has segmented the U.S. healthcare bioconvergence market based on drug discovery, nanorobotics for drug delivery, regenerative medicine, diagnostic and biological, bioelectronics, engineered living materials, optogenetics, precision medicine covering the revenue growth of each sub-segment from 2017 to 2030.
- U.S. Healthcare Bioconvergence Application Outlook (Revenue, USD Million, 2017-2030)
- Drug Discovery
- Nanorobotics for Drug Delivery
- Regenerative Medicine
- Diagnostic and Biological
- Bioelectronics
- Engineered Living Materials
- Optogenetics
- Precision Medicine
Reasons to subscribe to U.S. healthcare bioconvergence market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. healthcare bioconvergence market databook
-
Our clientele includes a mix of healthcare bioconvergence market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. healthcare bioconvergence market, including forecasts for subscribers. This country databook contains high-level insights into U.S. healthcare bioconvergence market from 2017 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. healthcare bioconvergence market report size, by application, 2017-2030 (US$M)
U.S. Healthcare Bioconvergence Market Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
